A leader in the rapid detection of pathogens, causing sepsis, T2 Biosystems Inc. (NASDAQ: TTOO) stock rose 43.125% to $2.290 in the pre-market session. At the last closing, Company was up 10.34% to $1.600.
T2 Biosystems is committed to optimizing patient safety and reducing healthcare costs by empowering doctors to treat patients quicker and more reliably than ever.T2 Biosystems products are powered by the patented T2 Magnetic Resonance technology and include the T2Dx Instrument, T2Candida Panel, T2Bacteria T2Resistance Panel, and T2SARS CoV-2 Panel. Besides additional drugs for the identification of bacterial and fungal pathogens and related antimicrobial resistance markers, and biothreat pathogens, T2 Biosystems has an active pipeline of potential products, including the T2Cauris Panel and T2Lyme Panel.
Recent News and Development:
On January 11, 2021, the Company announced that its T2SARS-CoV-2 Panel could detect multiple variants of the T2SARS-CoV-2 virus responsible for COVID-19 infections recently identified in the United Kingdom, South Africa, and the United States.
With the emergence of multiple strains of the COVID-19 virus, it is essential to continue to provide a diagnostic solution during this ongoing pandemic, said John Sperzel, CEO of T2 Biosystems.
After extensive analysis, we can confidently say that our T2SARS-CoV-2 Panel can continue to save lives by detecting multiple variants of the SARS-CoV-2 virus, demonstrating clinical sensitivity of over 95 specificities of over 100 percent.
The variants identified in South Africa (B.1.351) and United Kingdom (B.1.1.7) share many mutations, mirrored mainly in the S gene, which encodes the spike protein.
We’re living through the “golden age” of biotechnology, according to some experts. Science is opening new doors to the treatment and prevention of diseases previously unimaginable. Biotech stocks offer the possibility of huge returns for investors during this golden age.